Rifapentine

Active ingredient: Rifapentine

In short: Rifapentine tablets are indicated in adults and pediatric patients 12 years and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis. Rifapentine tablets must always be used in combination with one or more antituberculosis (anti-TB) drugs to which the is

Forms & strengthsRifapentine tablets are supplied as 150 mg reddish brown colored, round, beveled edge, biconvex, film-coated tablets debossed with "K" and "23" on one side and plain on other side.
LabelMacleods Pharmaceuticals Limited
Label updatedJul 08, 2026

What is Rifapentine used for?

Rifapentine tablets are indicated in adults and pediatric patients 12 years and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis. Rifapentine tablets must always be used in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible .

Limitations of Use

Do not use rifapentine tabletsmonotherapy in either the initial or the continuation phases of active antituberculous treatment.

Rifapentine tablets should not be used once weekly in the continuation phase regimen in combination with isoniazid (INH) in HIV-infected patients with active pulmonary tuberculosis because of a higher rate of failure and/or relapse with rifampin (RIF)-resistant organisms .

Rifapentine tablets have not been studied as part of the initial phase treatment regimen in HIV-infected patients with active pulmonary tuberculosis.

Rifapentine tablets are indicated in adults and pediatric patients 2 years and older for the treatment of latent tuberculosis infection caused by Mycobacterium tuberculosis in patients at high risk of progression to tuberculosis disease (including those in close contact with active tuberculosis patients, recent conversion to a positive tuberculin skin test, HIV-infected patients, or those with pulmonary fibrosis on radiograph) .

Limitations of Use

Active tuberculosis disease should be ruled out before initiating treatment for latent tuberculosis infection. …

Rifapentine dosage

Rifapentine tablets are only recommended for the treatment of active pulmonary tuberculosis caused by drug-susceptible organisms as part of regimens consisting of a 2-month initial phase followed by a 4-month continuation phase.

Rifapentine tablets should not be used in the treatment of active pulmonary tuberculosis caused by rifampin-resistant strains.

Initial phase (2 Months): Rifapentine tablets should be administered at a dose of 600 mg twice weekly for two months as directly observed therapy (DOT), with an interval of no less than 3 consecutive days (72 hours) between doses, in combination with other antituberculosis drugs as part of an appropriate regimen which includes daily companion drugs such as isoniazid (INH), ethambutol (EMB) and pyrazinamide (PZA).

Continuation phase (4 Months): Following the initial phase (2 months), continuation phase (4 months) treatment consists of rifapentine tablets 600 mg once weekly for 4 months in combination with isoniazid or another appropriate antituberculosis agent for susceptible organisms administered as directly observed therapy.

Rifapentine tablets should be administered once weekly in combination with isoniazid for 12 weeks as directly observed therapy.

Adults and pediatric patients 12 years and older: The recommended dose of rifapentine tablets should be determined based on weight of the patient up to a maximum of 900 mg once weekly . The recommended dose of isoniazid is 15 mg/kg (rounded to the nearest 50 mg or 100 mg) up to a maximum of 900 mg once weekly for 12 weeks.

Pediatric Patients2 to 11 years: The recommended dose of rifapentine tablets should be determined based on weight of the patient up to a maximum of 900 mg once weekly . The recommended dose of isoniazid is 25 mg/kg (rounded to the nearest 50 mg or 100 mg) up to a maximum of 900 mg once weekly for 12 weeks.

Table 1: Weight Based Dose of Rifapentine Tablets in the Treatment of Latent Tuberculosis Infection

Weight range | Rifapentine tablets dose | Number of Rifapentine tablets

10-14 kg | 300 mg | 2

14.1-25 kg | 450 mg | 3

25.1-32 kg | 600 mg | 4

32.1-50 kg | 750 mg | 5

>50 kg | 900 mg | 6

Take rifapentine tablets with meals. Administration of rifapentine tablets with a meal increases oral bioavailability and may reduce the incidence of gastrointestinal upset, nausea, and/or vomiting .

For patients who cannot swallow tablets, the tablets may be crushed and added to a small amount of semi-solid food, all of which should be consumed immediately .

How to take Rifapentine — instructions & advice from the label

Advise patient to read FDA-approved patient labeling (Medication Guide).

Treatment Adherence

Emphasize the importance of compliance with the full course of therapy, and the importance of not missing any doses of rifapentine tablets or companion medications in the treatment of active pulmonary tuberculosis or the treatment of latent tuberculosis infection.

Hypersensitivity Reactions

Inform patients that rifapentine tablets may cause hypersensitivity reactions. Signs and symptoms of this reaction may include a flu-like illness, hypotension, urticaria, angioedema, bronchospasm, conjunctivitis, thrombocytopenia or neutropenia. Anaphylaxis may also occur .

Inform patients of signs and symptoms of hypersensitivity reactions and advise them to stop the medication and contact their healthcare provider if they experience any of these symptoms.

Severe Cutaneous Adverse Reactions

Advise patients about the signs and symptoms of serious skin manifestations. Instruct patients to stop taking rifapentine tablets immediately and promptly report the first signs or symptoms of skin rash, mucosal lesions, or any other sign of hypersensitivity . …

Warnings & precautions

Do not take this medicine if: Rifapentine tablets are contraindicated in patients with a history of hypersensitivity to rifamycins.

Elevations of liver transaminases may occur in patients receiving rifapentine tablets . Patients on rifapentine tablets should be monitored for symptoms of liver injury.

Patients with abnormal liver tests and/or liver disease or patients initiating treatment for active pulmonary tuberculosis should only be given rifapentine tablets in cases of necessity and under strict medical supervision. In such patients, obtain serum transaminase levels prior to therapy and every 2 to 4 weeks while on therapy. Discontinue rifapentine tablets if evidence of liver injury occurs.

Hypersensitivity reactions may occur in patients receiving rifapentine tablets. Signs and symptoms of these reactions may include hypotension, urticaria, angioedema, acute bronchospasm, conjunctivitis, thrombocytopenia, neutropenia or flu-like syndrome (weakness, fatigue, muscle pain, nausea, vomiting, headache, fever, chills, aches, rash, itching, sweats, dizziness, shortness of breath, chest pain, cough, syncope, palpitations). There have been reports of anaphylaxis .

Monitor patients receiving rifapentine tablets therapy for signs and/or symptoms of hypersensitivity reactions. If these symptoms occur, administer supportive measures and discontinue rifapentine tablets.

Severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome have been reported in association with the use of rifapentine tablets treatment regimens in patients with active and latent tuberculosis. Discontinue rifapentine tablets at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity . …

Rifapentine side effects

The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling:

•Hepatotoxicity

•Hypersensitivity

•Severe Cutaneous Adverse Reactions

•Paradoxical Drug Reactions

•Discoloration of Body Fluids

•Clostridioides Difficile–Associated Diarrhea

•Porphyria

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Active Pulmonary Tuberculosis

Rifapentine tablets were studied in a randomized, open label, active-controlled trial of HIV-negative patients with active pulmonary tuberculosis. The population consisted primarily of male subjects with a mean age of 37 ± 11 years. In the initial 2-month phase of treatment, 361 patients received rifapentine tablets 600 mg twice a week in combination with daily isoniazid, pyrazinamide, and ethambutol and 361 subjects received rifampin in combination with isoniazid, pyrazinamide and ethambutol all administered daily. Ethambutol was discontinued when drug susceptibly testing was known. During the 4-month continuation phase, 317 patients in the rifapentine tablets group continued to receive rifapentine tablets 600 mg dosed once weekly with isoniazid and 304 patients in the rifampin group received twice weekly rifampin and isoniazid. …

Drug interactions

Rifapentine is an inducer of CYP450 enzymes. Concomitant use of rifapentine tablets with other drugs metabolized by these enzymes, such as protease inhibitors and certain reverse transcriptase inhibitors, may cause a significant decrease in plasma concentrations and loss of therapeutic effect of the protease inhibitor or reverse transcriptase inhibitor .

Once-weekly coadministration of 900 mg rifapentine tablets with the antiretroviral fixed-dose combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in HIV-infected patients did not result in any substantial change in steady state exposures of efavirenz, emtricitabine, and tenofovir. No clinically significant change in CD4 cell counts or viral loads were noted .

Rifapentine tablets may reduce the effectiveness of hormonal contraceptives. Patients using hormonal contraception should be advised to use an alternative non-hormonal contraceptive method or add a barrier method of contraception during treatment with rifapentine tablets.

Rifapentine is an inducer of cytochromes P450 3A4 and P450 2C8/9. Therefore, rifapentine tablets may increase the metabolism of other coadministered drugs that are metabolized by these enzymes. …

About this medicine

Rifapentine tablets for oral administration contains 150 mg of the active ingredient rifapentine per tablet.

The 150 mg tablets also contain, as inactive ingredients: calcium stearate, colloidal silicon dioxide, disodium EDTA, hydroxypropyl cellulose, iron oxide red, low substituted hydroxy propyl cellulose, microcrystalline cellulose, polyethylene glycol, pregelatinized starch, sodium ascorbate, sodium lauryl sulfate, sodium starch glycolate, talc, titanium dioxide and polyvinyl alcohol - part. hydrolyzed.

Rifapentine is a rifamycin derivative antimicrobial and has a similar profile of microbiological activity to rifampicin. The molecular weight is 877.04.

The molecular formula is C47H64N4O12.

The chemical name for rifapentine is rifamycin, 3-[[(4-cyclopentyl-1-piperazinyl)imino]methyl]- or 3-[N-(4-cyclopentyl - 1-piperazinyl)formimidoyl] rifamycin or 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-cyclopentyl-l-piperazinyl)-formimidoyl]-2,7-(epoxypentadeca[1,11,13] trienimino)naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f95d726e-5a09-48dd-b719-e4400fb91c8f. Read the full official label on DailyMed.

Related medicines

Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin